Small molecule inhibitors that target the SH2 domain of STAT3 (e.g., C188-9, OPB-31121, OPB-51602, W2014-S, BBI-608) have demonstrated potent in vitro and in vivo anti-tumor activity in NSCLC models [70,236,237,238]. This evidence concerns the gene STAT3 and neoplasm.